STOCK TITAN

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options totaling 10,700 shares to two new employees as a part of their inducement awards. This follows NASDAQ Listing Rule 5635(c)(4) and aims to attract talent to the company. The options were granted at an exercise price of $4.42 per share, corresponding to the closing stock price on November 15, 2022. The options will vest over four years, with the first 25% vesting on the anniversary of the grant date. EyePoint is focused on developing treatments for serious eye disorders using its Durasert® technology.

Positive
  • Granting of stock options to attract new talent.
  • Exercise price set at $4.42, matching market price.
Negative
  • Increased compensation expenses due to stock options.
  • -

WATERTOWN, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 10,700 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on November 15, 2022. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $4.42 per share, the closing price of EyePoint Pharmaceuticals’ common stock on November 15, 2022. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

For EyePoint Pharmaceuticals:

Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com


FAQ

What are the recent stock options granted by EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals granted 10,700 stock options to two new employees on November 15, 2022.

What is the exercise price for the stock options granted by EYPT?

The exercise price for the stock options is $4.42 per share.

How long is the vesting period for the stock options granted by EyePoint?

The stock options vest over four years, with 25% vesting on the first anniversary.

What is the purpose of the stock options granted by EYPT?

The stock options are inducement awards to attract new talent to the company.

Which NASDAQ rule did EyePoint Pharmaceuticals follow for the stock options grant?

The stock options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

EYPT Rankings

EYPT Latest News

EYPT Stock Data

485.95M
65.07M
1.14%
93.48%
14.47%
Biotechnology
Laboratory Analytical Instruments
Link
United States of America
WATERTOWN